HOOKIPA shareholders approve doubling authorized shares and authorize reverse split

HOOKIPA Pharma Inc.

Authorized common stock increased from 200M to 400M shares; approved by 64.8M for, 3.4M against.
Shareholders authorized board to implement reverse stock split (1:2 to 1:10) before June 17, 2025; 63.4M for, 4.7M against.
Directors Timothy Reilly and Malte Peters elected to Class II with 51.9M and 53.9M votes respectively.
Ratification of PwC Wirtschaftsprüfung GmbH as independent auditor for FY2024 approved (67.6M for).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.